Skip to main content
SpringerLink
Log in

Buserelin as a Single Agent or in Combination with the Antiandrogen Flutamide in the Treatment of Advanced Male Breast Cancer

  • Conference paper
Book cover LH-RH Agonists in Oncology

  • 46 Accesses

Abstract

Cancer of the male breast is a very rare disease. It accounts for approximately 1% of all breast cancers and 0.2%–1% of all male cancers, without correlation to religion, geography, race, or occupation. Breast carcinoma in men is generally diagnosed at a more advanced stage and in older age groups (predominantly seventh decade) than breast cancer in women. Compared to women with similar prognostic variables, however, the general pattern of survival rates seems to be similar in both sexes [1,3, 10,18, 28].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adami H-O, Holmberg L, Malker B, Ries L (1985) Long-term survival in 406 males with breast cancer. Br J Cancer 52: 99–103

    Article  PubMed  CAS  Google Scholar 

  2. Becher R, Hoffken K, Pape H, Schmidt CG (1981) Tamoxifen treatment before orchiectomy in advanced breast cancer in men. N Engl J Med 305: 169–170

    PubMed  CAS  Google Scholar 

  3. Crichlow RW (1974) Breast cancer in men. Semin Oncol 1: 145–152

    PubMed  CAS  Google Scholar 

  4. Evans RM, Doelle GC, Lindner J, Bradley V, Rabin D (1984) A luteinizing hormone-releasing hormone agonist decreases biological activity and modifies chromatographic behavior of luteinizing hormone in man. J Clin Invest 73: 262–266

    Article  PubMed  CAS  Google Scholar 

  5. Everson RB, Lippman ME, Thompson EB, McGuire WL, Wittliff JL, De Sombre ER, Jensen EV, Singhakowinta A, Brooks SC Jr, Neifeld JP (1980) Clinical correlations of steroid receptors and male breast cancer. Cancer Res 40: 991–997

    PubMed  CAS  Google Scholar 

  6. Farrow JH, Adair FE (1942) Effect of orchiectomy on skeletal metastases from cancer of the male breast. Science 95: 654

    Article  PubMed  CAS  Google Scholar 

  7. Harris AL, Dowsett M, Stuart-Harris R, Smith IE (1986) Role of aminoglutethimide in male breast cancer. Br J Cancer 54: 657–660

    Article  PubMed  CAS  Google Scholar 

  8. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289 - 1294

    Article  PubMed  CAS  Google Scholar 

  9. Kahan A, Delrieu F, Amor B, Chiche R, Steg A (1984) Disease flare induced by D-Trp-LH-RH analogue in patients with metastatic prostatic cancer. Lancet I: 971–972

    Article  Google Scholar 

  10. Kantarjian H, Yab H-Y, Hortobagyi G, Buzdar A, Blumenschein G (1983) Hormonal therapy for metastatic male breast cancer. Arch Intern Med 143: 237–240

    Article  PubMed  CAS  Google Scholar 

  11. Klijn JGM (1984) Long-term LH-RH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med Oncol Tumor Pharmacother 1: 123–128

    PubMed  CAS  Google Scholar 

  12. Kraybill WG, Kaufman R, Kinne D (1981) Treatment of advanced male breast cancer. Cancer 47: 2185–2189

    Article  PubMed  CAS  Google Scholar 

  13. Labrie F, Dupont A, Belanger A, Edmont J, Monfette G (1984) Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci USA 81: 3861–3863

    Article  PubMed  CAS  Google Scholar 

  14. Labrie F, Dupont A, Belanger A, Lachance R, Giguere M (1985) Long-term treatment with luteinizing hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Br Med J 291: 369–370

    Article  CAS  Google Scholar 

  15. Li MC, Janelli DE, Kelly EJ, Kashiwabara H, Kim RH (1970) Metastatic carcinoma of the male breast treated with bilateral adrenalectomy and chemotherapy. Cancer 25: 678–681

    Article  PubMed  CAS  Google Scholar 

  16. Lopez M (1985) Cyproterone acetate in the treatment of metastatic cancer of the male breast. Cancer 55: 2334–2336

    Article  PubMed  CAS  Google Scholar 

  17. Lopez M, di Lauro L, Papaldo P, Lazzaro B (1985) Chemotherapy in metastatic male breast cancer. Oncology 42: 205–209

    Article  PubMed  CAS  Google Scholar 

  18. Meyskens FL, Tormey DC, Neifeld JP (1976) Male breast cancer: a review. Cancer Treat Rev 3: 83–93

    Article  PubMed  Google Scholar 

  19. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214

    Article  PubMed  CAS  Google Scholar 

  20. Neifeld JP, Meyskens FL, Tormey DC, Javadpour N (1976) The role of orchiectomy in the management of advanced male breast cancer. Cancer 37: 992–995

    Article  PubMed  CAS  Google Scholar 

  21. Nirmul D, Pegoraro RJ, Jialal I, Naidoo C, Joubert SM (1983) The sex hormone profile of male patients with breast cancer. Br J Cancer 48: 423–427

    Article  PubMed  CAS  Google Scholar 

  22. Pannuti F, Martoni A, Busutti L, Gramellini M, Piaña E (1982) High-dose medroxyprogesterone acetate in advanced male breast cancer. Cancer Treat Rep 66: 1763–1765

    PubMed  CAS  Google Scholar 

  23. Parmar H, Phillips RH, Lightman SL, Edwards L, Allen L, Schally AV (1985) Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet II: 1201–1205

    Google Scholar 

  24. Patel JK, Nemoto T, Dao TL (1984) Metastatic breast cancer in males. Assessment of endocrine therapy. Cancer 53: 1344–1346

    Article  PubMed  CAS  Google Scholar 

  25. Patterson JS, Battersby LA, Bach BK (1980) Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep 64: 801–804

    PubMed  CAS  Google Scholar 

  26. Presant CA, Soloway MS, Klioze SS, Kosola JW, Yakabow AL, Mendez RG, Kennedy PS, Wyres MR, Naessig VL, Ford KS (1985) Buserelin as primary therapy in advanced prostatic carcinoma. Cancer 56: 2416–2419

    Article  PubMed  CAS  Google Scholar 

  27. Redding TW, Schally AV (1981) Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 78: 6509–6512

    Article  PubMed  CAS  Google Scholar 

  28. Ribeiro G (1985) Male breast carcinoma - a review of 301 cases from the Christie Hospital and Holt Radium Institute, Manchester. Br J Cancer 51: 115–119

    Article  PubMed  CAS  Google Scholar 

  29. Schally AV, Redding TW, Comaru-Schally AM (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep 68: 281–289

    PubMed  CAS  Google Scholar 

  30. Scheulen ME, Becher R, Hoffmann B, Hoffken K, Schmidt CG (1984) Hormonal therapy and chemotherapy for male breast cancer. Verh Dtsch Krebs Ges 5: 619

    Google Scholar 

  31. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT, Comaru-Schally AM, Schally AV (1982) Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 79: 1658–1662

    Article  PubMed  CAS  Google Scholar 

  32. Treves N (1959) The treatment of cancer, especially inoperable cancer, of the male breast by ablative surgery (orchiectomy, adrenalectomy, and hypophysectomy) and hormone therapy (estrogens and corticosteroids). An analysis of 42 patients. Cancer 12: 820–832

    Article  PubMed  CAS  Google Scholar 

  33. Vilchez-Martinez JA, Pedroza E, Arimura A, Schally AV (1979) Paradoxical effects of D-Trp6- luteinizing hormone-releasing hormone on the hypothalamic-pituitary-gonadal axis in immature female rats. Fertil Steril 31: 677–682

    PubMed  CAS  Google Scholar 

  34. Vorobiof DA, Falkson G (1987) Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer. Cancer 59: 688–689

    Article  PubMed  CAS  Google Scholar 

  35. Wenderoth UK, Jacobi GH (1983) Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate. A new approach to the classical concept. World J Urol 1: 40–48

    Article  Google Scholar 

  36. Williams MR, Walker KJ, Turkes A, Blarney RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53: 629–636

    Article  PubMed  CAS  Google Scholar 

  37. Zubrod CG, Schneiderman M, Frei III E, Brindley C, Gold GL, Shnider B, Oviedo R, Gorman J, Jones R, Jonsson U, Colsky J, Chalmers T, Ferguson B, Dederick M, Holland J, Selawry O, Regelson W, Lasagna L, Owens Jr. AH (1960) Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and Methylene thiophosphoramide. J Chron Dis 11: 7–21

    Article  Google Scholar 

Download references

Authors
  1. N. Niederle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Doberauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. E. Scheuten
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. G. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Hufelandstr. 55, D-4300, Essen 1, Federal Republic of Germany

    Klaus Höffken

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Niederle, N., Doberauer, C., Scheuten, M.E., Schmidt, C.G. (1988). Buserelin as a Single Agent or in Combination with the Antiandrogen Flutamide in the Treatment of Advanced Male Breast Cancer. In: Höffken, K. (eds) LH-RH Agonists in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73530-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73530-1_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73532-5

  • Online ISBN: 978-3-642-73530-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation